Skip to main content
Premium Trial:

Request an Annual Quote

Biosearch Acquires Rights to TurboFish Technology

NEW YORK (GenomeWeb News) – Biosearch Technologies today announced it has acquired the exclusive worldwide rights to the turboFISH technology.

As a result, the Petaluma, Calif.-based firm maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers University, it said.

TurboFish is a method for rapid single molecule RNA FISH. In a statement, Marc Beal, director of corporate development and licensing at Biosearch, said, "Point-of-care, point-of-contact, hospital bedside, and immediate care facilities are now target markets for real-time gene expression analysis using turboFISH. Extending turboFISH into the [operating room] for intraoperative analysis may allow for real-time cancer diagnostics, eliminating the need, ambiguities, and procedure of formalin fixation and paraffin embedding tissues for days-later analysis."

Financial and other terms of the deal were not disclosed.

Biosearch recently acquired a majority stake in LightSpeed Genomics. The two firms are co-developing a gene expression platform, optimized to work on Stellaris RNA FISH assays for detecting and quantifying single molecular RNA targets within individual cells.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.